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MLC trackingBackground and purpose: The purpose of this work is to present the clinical experience from the first-in-
human trial of real-time tumor targeting via MLC tracking for stereotactic ablative body radiotherapy
(SABR) of lung lesions.
Methods and materials: Seventeen patients with stage 1 non-small cell lung cancer (NSCLC) or lung metas-
tases were included in a study of electromagnetic transponder–guided MLC tracking for SABR
(NCT02514512). Patients had electromagnetic transponders inserted near the tumor. An MLC tracking
SABR plan was generated with planning target volume (PTV) expanded 5 mm from the end-exhale gross
tumor volume (GTV). A clinically approved comparator plan was generated with PTV expanded 5 mm
from a 4DCT-derived internal target volume (ITV). Treatment was delivered using a standard linear accel-
erator to continuously adapt the MLC based on transponder motion. Treated volumes and reconstructed
delivered dose were compared between MLC tracking and comparator ITV-based treatment.
Results: All seventeen patients were successfully treated with MLC tracking (70 successful fractions). MLC
tracking treatment delivery time averaged 8 minutes. The time from the start of CBCT to the end of treat-
ment averaged 22 minutes. The MLC tracking PTV for 16/17 patients was smaller than the ITV-based PTV
(range 1.6% to 44% reduction, or 0.6 to 18 cc). Reductions in mean lung dose (27 cGy) and V20Gy
(50 cc) were statistically significant (p < 0.02). Reconstruction of treatment doses confirmed a statistically
significant improvement in delivered GTV D98% (p < 0.05) from planned dose compared with the ITV-
based plans.
Conclusion: The first treatments with lung MLC tracking have been successfully performed in seventeen
SABR patients. MLC tracking for lung SABR is feasible, efficient and delivers high-precision target dose
and lower normal tissue dose.
 2020 The Author(s). Published by Elsevier B.V. Radiotherapy and Oncology 155 (2021) 131–137 This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Tumor motion in the thorax and abdomen is three dimensional,
complex and can vary within and between fractions [1,2]. Motion
during treatment may exceed that measured during the 4DCT used
for planning [3–5]. This motion complexity is optimally managed
by real-time adaptive radiation therapy, where the radiation
beam-target alignment is maintained during treatment obviatingthe need for an ITV. Real-time adaptation corrects the delivery
for motion at treatment, including motion variations and baseline
shifts. The clinical potential of such techniques should enable fide-
lity of dose painting to targets (with functional imaging) for
improved outcomes and shrinking of high dose volumes to further
alleviate treatment related toxicity. Inherent safety is achieved
from the real-time motion monitoring during treatment delivery
beyond that of pre-treatment imaging.
Real-time adaptive radiotherapy has been clinically imple-
mented in the CyberKnife system [6] (Accuray Inc. Sunnyvale,
USA), RadiXact [7], (Accuray Inc. Sunnyvale, USA) and Vero systems
[8] (BrainLab AG, Feldkirchen, Germany) demonstrating an
MLC tracking lung SABRincreased target accuracy [9–11]. MLC tracking is a form of real-
time adaptive radiotherapy enabled on a conventional linear accel-
erator (linac) utilizing the MLC to adapt to location and pose
changes during treatment representing a potentially highly acces-
sible motion management solution. First experimentally conceptu-
alized in 2001 [12], MLC tracking has been implemented on all
major linac vendors (Varian [13], Siemens [14] and Elekta
[15,16]) in a research setting and was first clinically implemented
in 2013 for prostate cancer [17]. The preliminary result for the first
lung SABR patient was reported previously [18].
The present study reports the results of the first clinical trial of
real-time adaptive radiotherapy using electromagnetic
transponder-guided MLC tracking for lung SABR. We report on
the feasibility, efficiency, dosimetric accuracy, and clinical out-
comes of the MLC tracking treatments.Methods and materials
Seventeen patients with primary NSCLC (n = 7) or metastases
(n = 10) underwent electromagnetic transponder-guided MLC
tracking in this ethics-approved clinical trial (NCT02514512). A
technical summary of the MLC tracking is provided in
Supplementary Materials. The patient cohort is summarized in
Table 1.
The study outline is shown in Fig. 1. The primary hypothesis
was that MLC tracking is feasible. Treatment efficiency was mea-
sured. Secondary outcomes included: evaluation of transponder
implantation safety and migration, comparison of target volumes
between MLC tracking and ITV-based, comparison of treatment
plans between MLC tracking and ITV-based, comparison of deliv-
ered vs. planned dose between MLC tracking and ITV-based, and
recording patient outcomes. Further study results are provided inTable 1
Characteristics of 17 patients who underwent radiotherapy.
Variable n = 17 (%)
Age at recruitment (y)





Primary non-small cell lung cancer 7 (41)
Metastases* 10 (59)
Lesion size (cc)






Lower left lobe 4 (24)
Lower right lobe 6 (35)
Upper left lobe 3 (18)
Upper right lobe 3 (18)
Lingula 0 (0)
Middle right lobe 1 (6)
Fractionation, Gy (No. fractions)
48 (4) 15 (88)




Lateral decubitus 1 (6)
Peak-to-peak tumor motion from 4DCT, cm
Mean (range) 0.9 (0.3–1.8)
*Primary site for metastases were (n): colorectal (3), head and neck (2), endometrial
(1), pancreas (1), hepatocellular carcinoma/liver (1), thyroid (1), renal cell cancer
(1). Only individual metastases were treated per patient.
132Supplementary Materials, including geometric accuracy, excursion
rate, patient reported outcomes and analysis of visual feedback.
Primary Endpoint – Feasibility of MLC tracking. The primary
endpoint of feasibility is defined as successful delivery of at least
90% of the treatment fractions. A successful delivery requires cor-
rect software control of the MLC to follow the target motion with-
out MLC tracking software failure. The primary hypothesis was
tested using maximum likelihood estimation (MATLAB binofit
function, MathWorks, USA).
Endpoint – Treatment efficiency. The mean time taken for CBCT
imaging and review (CBCT start to the start of the first treatment
field) and the mean time for treatment delivery (first treatment
field to last) was recorded from the logfiles from each fraction.
Secondary Endpoint – Transponder implantation, migration,
and motion. Two (n = 3) or three (n = 14) cylindrical anchored lung
transponders (14 mm long, 2 mm diameter) were implanted under
sedation one week prior to simulation using standard fiber optic
bronchoscopy with X-ray image guidance. Transponder implanta-
tion was planned to surround the lesion. Prior to treatment, plan-
ning contours for PTV and transponders were overlaid on the
CBCT scan to assess potential migration and alignment. During
treatment the transponder location is transmitted 25 times per sec-
ond with sub-mm accuracy [19,20]. Fluoroscopic X-ray imaging of
the lung was acquired at two orthogonal angles for 2–3 breaths to
visually inspect transponder/lesion motion prior to each treatment.
Transponder motion was recorded from 4DCT, CBCT and fluo-
roscopy at treatment for quantitative assessment. A tumor excur-
sion percentage is reported as the percentage of time that the
lesion moves outside the PTV during treatment delivery.
Secondary Endpoint – Comparison of PTV between MLC track-
ing and ITV-based plans. A planning 4DCT scan was performed
using an external surrogate for respiratory motion, the Varian
Real-time Position Management (RPM) system (Varian Medical
Systems, Palo Alto, CA), with the patient free-breathing and posi-
tioned in a vacuum immobilization device with arms above head.
Contours for treatment planning were drawn for MLC tracking,
and for comparison, to be used if MLC tracking was unavailable or
failed, for an ITV-based plan. MLC tracking contours were drawn on
the end-of-exhale phase as a reference phase to define the GTV
with the clinical target volume (CTV) defined as being equal to
the GTV. A 5 mm expansion was applied to form the PTV. The
end-of-exhale phase assures a proper localization and delineation
of the tumor [21–23] while the 5 mm margin has been described
in the literature to be sufficient to account for tracking system
latency up to 500 ms [24] and differences in tumor sizes and shape
during respiration [25]. The exhale phase CT scan is likely to have
the fewest imaging artifacts, and having the smallest lung volume,
is likely to over- rather than under-estimate the actual lung dose.
Contours for the ITV-based plan were derived from the 4DCT which
included the union of GTVs in each breathing phase. The ITV was
expanded by 5 mm to create the PTV. We tested the hypothesis
that PTV for MLC tracking will be smaller than for ITV-based
planning. This hypothesis was considered statistically significant
if p-value <0.05 using the Wilcoxon signed rank test.
Secondary Endpoint – Comparison of MLC tracking and ITV-
based plan dosimetry. Treatment plans were created in the Eclipse
planning system (v13.6, Varian Medical Systems, Palo Alto) for a 6
MV dual RapidArc delivery utilizing the AAA algorithm. The colli-
mator was angled to align the MLC leaves with the major motion
axis of the lesion (i.e. superior-inferior in most cases) and the arcs
rotated between 0 and 180 degrees (Varian IEC). MLC tracking
plans utilized the end-of-exhale phase as a reference phase for
dose calculation. The ITV-based plan was calculated on a mean
CT image from 4DCT. Both plans met the dose volume criteria of
RTOG 0915 [26] and were clinically approved. The fractionation
scheme was either 48 Gy in four fractions or 50 Gy in five fractions
Fig. 1. Study outline. Patients received MLC tracking treatment. Primary outcome is feasibility with a range of geoemtric, dosimetric and clinical secondary outcomes. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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lung V20Gy are defined per RTOG as lung subtracting GTV/ITV.
We tested the hypothesis that MLC tracking provided lower lung
dose (MLD and V20Gy) compared to ITV-based planning is statisti-
cally significant if p-value <0.05 using the Wilcoxon signed rank
test.
Secondary Endpoint – Comparison of delivered vs planned
dose between MLC tracking and ITV-based plans. At treatment
sessions, the patient was aligned to lasers in the vacuum immobi-
lization device. Motion of transponders were monitored and
aligned for final patient positioning in the treatment room. For
each fraction, CBCT was acquired and a best-fit alignment to the
transponders was performed. The PTV contour was overlaid to
review tumor coverage.
The dose reconstruction method of Poulsen [27] was applied to
estimate the delivered dose with MLC tracking and ITV-based
plans, as described previously [28]. As 4D CBCT was not available
for this study, the dose reconstruction was performed on the plan-
ning 4DCT scan. Briefly, for targets, transponder motion traces and
MLC logfiles were encoded into the treatment plan recalculated in
the treatment planning system on the planning dataset. The varia-
tion in delivered dose across fractions was compared against the
planned dose for MLC tracking and the ITV-based plans. For each
patient we record the range of [planned-delivered] dose for each
metric e.g. GTV D100% as a measure of fidelity in delivery.
Secondary Endpoint – Patient outcomes (survival, toxicity and
quality of life). For all patients we collected any site of failure (lo-
cal, regional or distant). Local failure was based on either PET avid
disease, positive biopsy findings or progressive growth on subse-
quent CTs as deemed by the Multi-Disciplinary Team (MDT).
Patients had CT scans prior to clinical follow-up, at 3 month inter-
vals during the first 2 years followed by 4 month intervals in the
3rd and 4th years and a 6 month interval in the 5th year. Toxicity
was assessed utilizing the Common Terminology Criteria for
Adverse Events (CTCAE v4.0) at baseline and every 3 months after
treatment to 2 years. Quality of life was assessed using the Euro-
pean Organization for Research and Treatment of Cancer (EORTC)
Quality of Life Questionnaire-Core 30 (QLQ-C30) and the Quality
of Life Questionnaire Lung Cancer 13 (QLQ-LC13). Patients were
asked to complete the EORTC-QLQ-C30, EORTC-QLQ-LC13 and Pain
Thermometer at baseline on initial visit, first day of treatment, last
day of treatment and every 3 months following treatment for
2 years. These results were reported in the Supplementary
Material.
Overall survival (OS) and progression free survival (PFS) are
estimated using the Kaplan-Meier method. Time to first failure is
estimated with cumulative incidence adjusting for competing133risks. Time to local failure is also estimated assuming that ongoing
assessments are made after other failures are observed.
Results
All 70 MLC tracking treatment fractions for 17 patients were
successful i.e. treated without failure of MLC tracking software.
Maximum likelihood analysis yielded an estimated success rate
of 100%, with 99% confidence intervals of (93%, 100%). Therefore,
we accept the primary hypothesis that MLC tracking is feasible.
The mean time taken for CBCT imaging and review was 14 min-
utes (range 4–50 min). The mean time for treatment delivery was 8
minutes (range 2–26 min). The mean time from start of CBCT to
end of last field was 22 minutes (range 15–40 min).
No bleeding, hematoma, leakage, infection or other complica-
tions were observed in relation to the transponder implantations.
For 3 patients, 1 of 3 implanted transponders was not tracked by
the Calypso system. For one of these patients, a transponder was
outside the detection volume; for the other two patients it was
shown that a group of two provided a superior surrogate based
on 4DCT review (and confirmed with fluoroscopy on first day).
No migration of any transponders between simulation and treat-
ment, or during treatment, was observed.
The mean lesion motion amplitude in the 4DCT scan was
5.9 mm (range 1.7–11.7 mm) in the superior-inferior (SI),
2.2 mm (range 0.9–5.5 mm) in the left–right (LR), and 3.9 mm
(range 1.2–12.9 mm) in the anterior-posterior (AP) direction. The
mean GTV motion amplitude during treatment was larger than at
4DCT, ranging from 2.4 – 39.4 mm in the SI, 1.5–13.4 mm in the
LR, and 1.6–19.8 mm in the AP directions. In one patient, a single
transponder was placed in a neighboring lobe, and all three
transponders were tracked.
Motion of the transponders during treatment was observed to
be larger than captured during CT simulation [4,18]. Motion
extending outside the PTV, a 5 mm expansion of the ITV, is
reported as the tumor excursion percentage. Data from the 17
patients estimates tumor excursion for the ITV-based plans would
have occurred on average 3.3%, 0.02%, and 0.7% of the time, in the
SI, LR, and AP directions respectively. Four patients exhibited an SI
excursion rate on at least one day of more than 5%. The average
(and range) of excursion rate for this subgroup was 15.4% (7.9–
24.5%), 16.1% (4.9–31.6%), 8.7% (3.3–14.9%), and 9.6% (0–27.5%).
Conventionally, SABR delivery does not deploy intra-treatment
tumor monitoring so any geometric miss would have been
undiscovered.
Fig. 2 shows the reducing PTV with MLC tracking relative to the
ITV-based PTV. The mean (standard deviation (SD), range) of the
Fig. 2. Scatter plot of MLC tracking PTV against ITV-based PTV. The dotted line
corresponds to the line of equality, while the thick solid line corresponds to the
linear regression fit (a ¼ 0:746, Pearson r ¼ 0:945). The shaded area represents the
95% confidence interval of the estimated regression slope (0:613;0:901Þ. The
reduction in PTV size between MLC tracking and ITV-based planning is significant
(p < 0.001).
Fig. 3. Percentage difference between accumulated planned and delivered GTV
dose per patient (n = 17) for key target dose metrics comparing MLC tracking (blue)
with ITV-based plans (red). Boxes indicate quartiles, median (line) and average
(cross), while whiskers indicate the minimum and maximum. Key: (ns) not
significant and (*) significant for p < 0.02). (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this article.)
MLC tracking lung SABRPTV with MLC tracking and ITV-based planning was 18.6 cc (11.4,
3.9–39.6) and 25.0 cc (14.2, 5.0–53.9), respectively. The mean (SD,
range) of the PTV reduction with MLC tracking was 26.4% (12.6%,
1.6–44.3%) or 6.4 cc (5.1 cc, 0.6 cc–17.7 cc) compared to the
ITV-based PTV. A single case (Patient 17) with PTV = 39 cc exhib-
ited a slightly larger PTV with MLC tracking (increase of 1.6% or
0.6 cc). The lesion for this patient experienced very small motion
along the SI direction (<3 mm) providing minimal internal margin
for motion. As CTV is contoured on average CT for ITV-based plan-
ning and on end-exhale phase image, the difference has been
attributed within the intra-observer uncertainty range of contour-
ing. The Wilcoxon signed-rank test p-value of the PTVs with MLC
tracking compared to those with ITV-based planning was less than
0.001, confirming the hypothesis that the PTV reduction is statisti-
cally significant.
All treatment plans for MLC tracking and for ITV-based planning
met the planning dose constraints. Planned MLD reduced from
2.91 Gy for ITV-based planning to 2.64 Gy for MLC tracking. In rel-
ative terms, MLD was reduced on average by 27 cGy (SD 40 cGy)
with reductions ranging from 37 (increase) to 123 cGy. This
reduction in MLD was statistically significant (Wilcoxon signed-
rank test p < 0.02). The volume of lung (excluding GTV) receiving
20 Gy was reduced from 297 cc for ITV-based planning to 247 cc
(8.7%) for MLC tracking. In relative terms, V20Gy was reduced by
50 cc (SD 52 cc) ranging from 20 (increase) to 196 cc with MLC
tracking. This reduction in V20Gy was statistically significant (Wil-
coxon signed-rank test p < 0.02). Five of seventeen patients demon-
strated a higher MLD and 1/17 patients demonstrated a higher lung
V20Gy with the MLC tracking plan despite having a smaller PTV.
This difference is attributed to a combination of factors including
small motion, dose calculation in the exhale phase rather than on
an average CT, and plan quality.
Dose reconstruction of the delivered target dose with MLC
tracking showed improved fidelity of the planned dose compared
to the ITV-based plan in terms of accuracy and reproducibility.
Fig. 3 shows the percentage difference between planned GTV dose
metrics (D100%, D98%, D95%, and D2%) and reconstructed deliv-
ered doses including actual motion. Average dosimetric delivery
accuracy was improved for D98% and D95% for the MLC tracking
plans compared with the ITV-based plans. Specifically, the mean
difference between planned and delivered GTV D100% was reduced134from 1.7% (ITV plan) to 1.1% (MLC tracking plan), 1.4% to
0.4% for D98% and 1.2% to 0.1% for D95%. GTV D2% difference
from planned increased with MLC tracking compared with ITV-
based by 1.1% on average and up to 3.7%. This increase in D2%
localized as a central hotspot is a common dose artifact for MLC
tracking [29]. PTV D98% for MLC tracking was 99.4 ± 1.4% (planned)
and 96.0 ± 3.9% (delivered) compared to ITV-based with
99.8 ± 20.6% (planned) and 92.0 ± 8.9% (delivered). PTV D2% for
MLC tracking was 116.2 ± 3.4% (planned) and 117.3 ± 3.8% (deliv-
ered) compared to ITV-based with 116.8 ± 4.5% (planned) and
116.6 ± 4.4% (delivered).
The delivered doses are more reproducible with MLC tracking
for D100%, D98% and D95%. The mean difference between treated
and planned GTV D100% was 1.1 ± 2.3% for MLC tracking and
1.7 ± 2.4% for ITV-based. Differences for GTV D98% was 0.4 ± 1.
4% for MLC tracking and 1.4 ± 1.7% for ITV-based. Differences for
GTV D95% was 0.1 ± 1.3% for MLC tracking and 1.2 ± 1.7% for
ITV-based. Differences for GTV D2% was 1.1 ± 1.4% with MLC track-
ing and 0.1 ± 1.6% for ITV-based.
Fig. 4 shows the best and worst case dose volume histograms
(DVHs) for MLC tracking patients assessed by difference in PTV
D95% values between plan and actual value. DVHs for all patients
are shown in Supplementary Fig. 1. Unlike previous experience
with MLC tracking for prostate where the same plan is used for
tracking and non-tracking, for lung SABR, the respiratory motion
led to different target volumes and different dose distributions
between tracking and non-tracking. Each day’s treatment delivery
will encounter different motion providing different delivery accu-
racy evident in the thin line DVH curves, as compared to the thick
lines marking the planned DVH. Fig. 5 shows dose distributions for
best and worst cases for both MLC tracking and ITV-based plans.
These dose distributions show the total dose over 4 or 5 fractions.
The median follow-up for our cohort of patients was
27.5 months with 5 deaths recorded, with 4 patients succumbing
to their disease. There were 2 local failures with a median time
to local failure of 17.0 months. The time to local failure for the
two failures were 9.8 and 24.1 months. The PFS for the entire group
was 16.8 months. There were 2 patients with CTCAE grade 2 toxi-
city (both pneumonitis), with no patients having grade 3 or greater
toxicity. Further detail including Quality of Life (QoL) data is pro-
vided in Supplementary Data.
Fig. 4. Dose Volume Histograms for ‘best’ and ‘worst’ cases for MLC tracking rated by difference between planned and delivered PTV D95% value. Planned dose (thick curves)
is shown against daily delivered doses at each fraction (thin curves: solid, dashed, dotted, and dot-dashed for 4 fractions). The GTV for MLC tracking (dark blue) and ITV (red),
as well as the normal lung (subtracting target) for MLC tracking (light blue) and ITV-based plan (orange) are shown. (For interpretation of the references to colour in this
figure legend, the reader is referred to the web version of this article.)
Fig. 5. Dose distributions for ‘best’ and ‘worst’ cases ranked by difference between planned and delivered PTV D95% value. GTV shown as blue contour and PTV as red contour.
All doses represent a full course of treatment. (a–d) MLC tracking examples. (e–h) ITV-based cases.
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MLC tracking lung SABRDiscussion
The first real-time adaptive trial using MLC tracking for lung
SABR has been performed. MLC tracking produced reductions in
PTV in line with other real-time motion management techniques,
such as CyberKnife [30], RadiXact [31] and Vero [22]. MLC tracking
is potentially highly accessible since it requires only software addi-
tional to a standard linac with real-time motion monitoring [32].
This study was designed to test feasibility of MLC tracking
across a typical lung SABR patient cohort with a range of disease
sites and tumors exhibiting large and small motion. We expected
MLC tracking to do no worse than the comparator ITV-based plans,
and within the accuracy of our reporting this has been demon-
strated for all courses of treatment. Some individual fractions
demonstrated inferior tumor dose coverage compared with the
plan. In these ‘worst’ cases, there were multiple contributing fac-
tors including system latency requiring prediction which intro-
duced uncertainty and error in the presence of irregular motion.
Real-time adaptation systems, such as RadiXact, Vero and Unity
have reported system latencies of 70 ms [31], 48 ms [22] and
20 ms [16], respectively. Commercial MLC tracking systems have
lower system latency than our research system (220 ms, see
Supplementary Materials) allowing a superior response to irregular
motion, which proved to be challenging to predict and control at
the time of treatment for some fractions in this study.
ITV-based planning will produce larger PTVs than respiratory
gated or breath hold techniques, which provide similar PTVs to
MLC tracking [33,34]. The mid-ventilation technique compares
similarly to ITV-based approach [28,35]. Despite this larger PTV,
the delivered dose with an ITV-based plan will be influenced pre-
dominantly by the tumor motion at treatment. We have shown
previously for this patient cohort, and elsewhere [3,5] that lesions
affected by respiratory motion generally exhibit (50%) greater
peak-to-peak motion at treatment than measured during 4DCT.
Importantly, baseline drifts were observed during treatment in this
cohort. Baseline drifts are deleterious to the accuracy of any deliv-
ery technique that operates without lesion motion management
during delivery. We used real-time transponder tracking to moni-
tor motion during setup, CBCT and treatment fractions with MLC
tracking activated. The notable wait time between CBCT and first
treatment field (mean 14 min; max 50 min) due to extra care with
alignment between transponders and soft tissue, rotation and
potential repeat CBCT, did not affect the accuracy of MLC tracking.
MLC tracking has been shown to deliver treatment with high
precision enabling reductions in dose delivered to healthy lung.
This study has shown reductions in MLD up to 123 cGy and aver-
age 27 cGy are achievable. MLD has been shown to indicate toxic-
ity. Barriger et al. [36] show rates of grade 2+ radiation
pneumonitis at 4.3% where MLD < 4 Gy, and 17.6% with
MLD > 4 Gy. Chang et al. [37] show an increase in grade 2+ radia-
tion pneumonitis with MLD above 6 Gy. In this study, all plans
(ITV-based and MLC tracking) met MLD constraints of 4 Gy and
therefore no lung toxicity reduction is expected for this cohort.
The secondary endpoints of the trial were patient outcomes.
The median follow-up for the cohort was 27.5 months. There were
2 local failures with the actuarial 1 year OS 88%, 2 year OS 88% and
1 year PFS 53%, 2 year 39%. The rate of grade 2 toxicity was low
(11.7%) with no higher grade 3–5 toxicity. For the QoL data please
see the Supplementary Material.
There were limitations to this study; patient orientation, inclu-
sion of patients with small motion, and study size. We would have
treated all of the patients in the supine orientation. However, lim-
itations with the detectable lesion depth (maximum of 17 cm) of
the motion monitoring equipment led to 7 of 17 patients requiring
non-standard prone or lateral decubitus orientation. Treatment in136prone orientation may have caused slower and less robust patient
setup compared to our standard supine orientation. As a feasibility
study, we included all patients to gain an understanding across a
range of clinical scenarios, no patient received a worse treatment.
Considering the rapid delivery and automation of real-time adap-
tation, we suggest that with care in patient selection (e.g. central
lesions) and implementation (e.g. gating if motion towards, not
away from, dose limiting structure) that MLC tracking should be
safe and efficient for all patients, not only those patients with
lower lobe disease. This study required 17 of 20 patients to achieve
statistical significance for primary hypothesis that MLC tracking is
feasible. A larger study is needed to draw conclusions on any clin-
ical benefit, though there are clear dosimetric benefits.
Real-time adaptive radiotherapy has been commercially avail-
able for 15 years; to date all versions have used kV X-rays,
transponders and/or optical surface tracking to synchronize treat-
ment delivery with lesion/surrogate centroid motion. The next
level of sophistication in real-time radiotherapy might be systems
that track real-time dose accumulation to a rigid or deforming tar-
get volume, or consider accumulated dose to organs at risk. Such
systems are emerging but require real-time anatomy as input to
link to real-time dose adaptation. MRI-Linacs have been imple-
mented with MLC tracking to provide high soft tissue contrast
for guidance [16,38], so when combined with real-time dose pre-
diction should lead to full automation in alignment, control and
delivery. For X-ray and optical guidance systems, there continues
to be development of motion models and direct tracking tech-
niques with increasing accuracy for a range of tumor targets.
Real-time adaptive radiotherapy aligns with contemporary areas
of development in intelligent systems and automation that should
see existing barriers overcome and such techniques deployed
broadly in the future.
In conclusion, the first trial with MLC tracking has been success-
fully performed in seventeen lung cancer patients. MLC tracking for
lung SABR is feasible, efficient and delivers high-precision target
dose and lower normal tissue dose.
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